NASDAQ: SCYXScynexis Inc Stock
$0.90-0.01 (-1.1%)
Updated Apr 17, 2025
SCYX Price
$0.90
Fair Value Price
-$0.16
Market Cap
$35.24M
52 Week Low
$0.73
52 Week High
$3.07
P/E
-2.05x
P/B
0.64x
P/S
15.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.75M
Earnings
-$21.29M
Gross Margin
100%
Operating Margin
-542.15%
Profit Margin
-568.3%
Debt to Equity
0.65
Operating Cash Flow
-$24M
Beta
1.19
Next Earnings
May 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SCYX Overview
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SCYX's potential to beat the market
- SCYX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
SCYX
RankedUnranked of 54
RankedUnranked of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.36 | A | |
| $24.65 | A | |
| $13.76 | A |
Be the first to know about important SCYX news, forecast changes, insider trades & much more!
SCYX News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SCYX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCYX ($0.90) is overvalued by 670.83% relative to our estimate of its Fair Value price of -$0.16 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SCYX ($0.90) is not significantly undervalued (670.83%) relative to our estimate of its Fair Value price of -$0.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SCYX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SCYX due diligence checks available for Premium users.
Valuation
SCYX fair value
Fair Value of SCYX stock based on Discounted Cash Flow (DCF)
Price
$0.90
Fair Value
-$0.16
Undervalued by
668.30%
SCYX ($0.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SCYX ($0.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SCYX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SCYX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.05x
Industry
20.48x
Market
27.98x
SCYX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.64x
Industry
1.99x
SCYX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SCYX's financial health
Profit margin
Revenue
$977.0k
Net Income
-$4.4M
Profit Margin
-453.7%
SCYX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SCYX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$90.6M
Liabilities
$35.6M
Debt to equity
0.65
SCYX's short-term assets ($72.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCYX's short-term assets ($72.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCYX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SCYX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.9M
Investing
-$2.6M
Financing
-$155.0k
SCYX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SCYX vs Pharmaceutical Stocks
Scynexis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.